The use of Mexidol® in children's neurological practice

Authors:
G.R. KHAMITOVA

Place of publication:
NEUROLOGY, 2012

Abstract:
The health of the younger generation is one of the most pressing issues in both medical, biological, and social terms, and is particularly significant in today's world. Effective prevention and treatment of neurological diseases in children are crucial tasks. Childhood neurological morbidity in the Republic of Bashkortostan ranks high not only in frequency but also in the severity of clinical manifestations. One in eight children out of every 1,000 is born with a neurological disorder, and one in ten of these children subsequently develops a disability. According to the United Nations, neurological disorders account for 30% of the 120 million children with disabilities. Decompensation of the consequences of nervous system damage in children, such as perinatal encephalopathy, neuroinfections, traumatic brain injury, and others, is frequently encountered in everyday clinical practice. It is possible that encephalopathies experienced in childhood lay the foundation for the development of a number of diseases in adults. When assessing the outcomes of brain injuries, the risk of neuropsychiatric disorders with learning disabilities, emotional-volitional, and psycho-speech disorders was found to be extremely high, ranging from 13% to 47%. Therefore, attention should be paid to adequate systematic treatment and early rehabilitation measures from the first months of a child's life. It is important to consider that children have a significantly greater adaptive capacity to restore impaired functions than adults, making it possible to prevent or minimize the severity of disability.